Attilla Ting

637 citations
17 papers · 467 · h-index 13

Impact in

  • Cancer Research
    • Protease and Inhibitor Mechanisms
  • Oncology
    • PARP inhibition in cancer therapy
    • Peptidase Inhibition and Analysis

Papers in

  • Molecular Biology 11
    • DNA Repair Mechanisms 5
    • Cancer therapeutics and mechanisms 4
    • DNA and Nucleic Acid Chemistry 3
  • Oncology 7
    • Peptidase Inhibition and Analysis 3
    • PARP inhibition in cancer therapy 3
Co-authors
S. Gerhardt (4 shared papers)Gillian M. Lamont (5 shared papers)David Hargreaves (2 shared papers)Frederick W. Goldberg (5 shared papers)David T. Beattie (4 shared papers)Julia Bárdos (3 shared papers)Roger J. Griffin (3 shared papers)Ian R. Hardcastle (3 shared papers)
Journals
Bioorganic & Medicinal Chemistry Letters (6 papers)Journal of Medicinal Chemistry (4 papers)Cancer Research (2 papers)ACS Medicinal Chemistry Letters (1 paper)Journal of Molecular Biology (1 paper)
Partner nations
United KingdomGermanyPoland

In The Last Decade

Attilla Ting

17 papers receiving 454 citations

Peers

Attilla Ting
Comparison fields: 5 of 72
  • Cancer Research 92
  • Oncology 164
  • Toxicology 15
  • Immunology and Allergy 24
  • Molecular Biology 267
Replace Marc R. Arnone with:
Marc R. Arnone United States
Laura L. Rokosz United States
Manfred Schudok Germany
Karen L. Milkiewicz United States
Zhonghui Lu United States
Mary Pat Beavers United States
Guoshun Luo China
Angela Seaton United Kingdom
Rachel E. Davis United States
Asaad Nematalla United States
Attilla Ting relative to Marc R. Arnone United States Marc R. Arnone's profile →
Citations per field
00.5×1.5×2.1×
Marc R. Arnone · 1×
Citations per year

Countries citing papers authored by Attilla Ting

Since Specialization
Citations

This map shows the geographic impact of Attilla Ting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Attilla Ting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Attilla Ting more than expected).

Fields of papers citing papers by Attilla Ting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Attilla Ting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Attilla Ting. The network helps show where Attilla Ting may publish in the future.

Co-authors

The 25 scholars most cited alongside Attilla Ting, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Attilla Ting Line = papers co-authored together Attilla Ting links everyone, so they are left out of the graph.

All Works

17 of 17 papers shown
#Work
1
Crystal Structures of Human ADAMTS-1 Reveal a Conserved Catalytic Domain and a Disintegrin-like Domain with a Fold Homologous to Cysteine-Rich Domains
Journal of Molecular Biology ·S. Gerhardt, G. Hassall, Paul Hawtin, Eileen McCall, Liz Flavell, Claire A. Minshull, David Hargreaves, Attilla Ting, Richard A. Pauptit, Andrew E. Parker, W. Mark Abbott
200768
2
Learning Medicinal Chemistry Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Rules from Cross-Company Matched Molecular Pairs Analysis (MMPA)
Journal of Medicinal Chemistry ·Christian Krämer, Attilla Ting, Hao Zheng, Jérôme Hert, Torsten Schindler, Martin Ståhl, Graeme R. Robb, James J. Crawford, Jeff Blaney, Shane Montague, Andrew G. Leach, Al G. Dossetter, Ed Griffen
201767
3
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
Journal of Medicinal Chemistry ·Frederick W. Goldberg, M. Raymond V. Finlay, Attilla Ting, David T. Beattie, Gillian M. Lamont, Charlene Fallan, Gail L. Wrigley, Marianne Schimpl, Martin Howard, Beth Williamson, Mercedes Vázquez–Chantada, Derek Barratt, Barry R. Davies, Elaine Cadogan, Antonio Ramos‐Montoya, Emma Dean
201966
4
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Cancer Research ·Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, Rajesh Odedra, H. Shelton Brown, Janneke E. Jaspers, Louise Jones, Charlotte Knights, Bastiaan Evers, Attilla Ting, Robert H. Bradbury, Marina Pajic, Sven Rottenberg, Jos Jonkers, David A. Rudge, Niall M.B. Martin, Keith W. Caldecott, Alan Lau, Mark J. O’Connor
201660
5
1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity
Journal of Medicinal Chemistry ·Céline Cano, Kappusamy Saravanan, Chris Bailey, Julia Bárdos, Nicola J. Curtin, Mark Frigerio, Bernard T. Golding, Ian R. Hardcastle, Marc Hummersone, Keith Menear, David R. Newell, Caroline J. Richardson, Kerry Shea, Graeme C.M. Smith, Pia Thömmes, Attilla Ting, Roger J. Griffin
201342
6
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology
Journal of Medicinal Chemistry ·Frederick W. Goldberg, Jason G. Kettle, Gillian M. Lamont, David Buttar, Attilla Ting, Thomas M. McGuire, Calum Cook, David T. Beattie, Pablo Morentin Gutierrez, Stefan Kavanagh, J.C. Komen, Aarti Kawatkar, Roger Clark, Lorna Hopcroft, Gareth Hughes, Susan E. Critchlow
202238
7
Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives
Organic & Biomolecular Chemistry ·K.M. Clapham, Tommy Rennison, Gavin O. Jones, Faye Craven, Julia Bárdos, Bernard T. Golding, Roger J. Griffin, Karen Haggerty, Ian R. Hardcastle, Pia Thömmes, Attilla Ting, Céline Cano
201220
8
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis
Bioorganic & Medicinal Chemistry Letters ·Chris De Savi, Andrew R. Pape, John G. Cumming, Attilla Ting, Peter D. Smith, Jeremy N. Burrows, Mark Mills, Chris Davies, Scott G. Lamont, David Milne, Calum Cook, Peter R. Moore, Yvonne Sawyer, S. Gerhardt
201118
9
DNA-dependent protein kinase (DNA-PK) inhibitors: Structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain
Bioorganic & Medicinal Chemistry Letters ·K.M. Clapham, Julia Bárdos, M. Raymond V. Finlay, Bernard T. Golding, Edward J. Griffen, Roger J. Griffin, Ian R. Hardcastle, Keith Menear, Attilla Ting, Paul Turner, Gail L. Young, Céline Cano
201018
10
Selective non zinc binding inhibitors of MMP13
Bioorganic & Medicinal Chemistry Letters ·Chris De Savi, Andrew Morley, Attilla Ting, Ian A. Nash, Kostas Karabelas, Christine Wood, Michael J. James, Stephen J. Norris, Galith Karoutchi, Neil Rankine, Gordon A. Hamlin, Philip A. MacFaul, David Ryan, Sarah V. Baker, David Hargreaves, S. Gerhardt
201118
11
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis
Bioorganic & Medicinal Chemistry Letters ·Chris De Savi, Andrew R. Pape, Yvonne Sawyer, David Milne, Chris Davies, John G. Cumming, Attilla Ting, Scott G. Lamont, Peter D. Smith, Jonathon Tart, Ken Page, Peter R. Moore
201113
12
Novel inhibitors of the αvβ3 integrin—lead identification strategy
Bioorganic & Medicinal Chemistry Letters ·David J. Elliot, Eleanor Henshaw, Philip A. MacFaul, Andrew Morley, Peter Newham, Keith T. Oldham, Ken Page, Neil Rankine, Paul T. Sharpe, Attilla Ting, Christine Wood
200912
13
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2
Bioorganic & Medicinal Chemistry Letters ·Chris De Savi, Andrew Morley, Ian A. Nash, Galith Karoutchi, Ken Page, Attilla Ting, S. Gerhardt
201112
14
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK
ACS Medicinal Chemistry Letters ·Frederick W. Goldberg, Attilla Ting, David T. Beattie, Gillian M. Lamont, Charlene Fallan, M. Raymond V. Finlay, Beth Williamson, Marianne Schimpl, Alexander R. Harmer, Oladipupo B. Adeyemi, Pär Nordell, Anna Cronin, Mercedes Vázquez–Chantada, Derek Barratt, Antonio Ramos‐Montoya, Elaine Cadogan, Barry R. Davies
20227
15
Expert System Assisted Pharmacophore Identification
Journal of Chemical Information and Computer Sciences ·Attilla Ting, Ross McGuire, AnnDee Johnson, Stuart Green
20006
16
Abstract DDT01-02: Discovery and first structural disclosure of AZD7648: A potent and selective DNA-PK inhibitor
Frederick W. Goldberg, Elaine Cadogan, Raymond Finlay, Antonio Ramos Montoya, David A. Beattie, Gillian M. Lamont, Charlene Fallan, Jacqueline H. Fok, Mercedes Vázquez–Chantada, Derek Barratt, Emma Dean, Jane Norris, Andrew T. Campbell, Anna Cronin, Joanna Harding, Attilla Ting, Simon J. Hollingsworth, Barry R. Davies
20191
17
Abstract DDT01-02: Discovery and first structural disclosure of AZD7648: A potent and selective DNA-PK inhibitor
Cancer Research ·Frederick W. Goldberg, Elaine Cadogan, Raymond Finlay, Antonio Ramos Montoya, David T. Beattie, Gillian M. Lamont, Charlene Fallan, Jacqueline H. Fok, Mercedes Vázquez–Chantada, Derek Barratt, Emma Dean, Jane Norris, Andrew D. Campbell, Anna Cronin, Joanna Harding, Attilla Ting, Simon J. Hollingsworth, Barry R. Davies
20191

About Attilla Ting

Attilla Ting is a scholar working on Molecular Biology, Oncology, Cancer Research, Toxicology and Computational Theory and Mathematics, having authored 17 papers that have together received 467 indexed citations. Recurring topics across this work include DNA Repair Mechanisms (5 papers), Cancer therapeutics and mechanisms (4 papers), Protease and Inhibitor Mechanisms (4 papers), Peptidase Inhibition and Analysis (3 papers), Computational Drug Discovery Methods (3 papers), DNA and Nucleic Acid Chemistry (3 papers), PARP inhibition in cancer therapy (3 papers) and Bioactive Compounds and Antitumor Agents (3 papers). The work is most often cited by research in Cancer Research (92 citations), Oncology (164 citations), Toxicology (15 citations), Immunology and Allergy (24 citations) and Molecular Biology (267 citations). Attilla Ting has collaborated with scholars based in United Kingdom, Germany and Poland. Frequent co-authors include S. Gerhardt, Gillian M. Lamont, David Hargreaves, Frederick W. Goldberg, David T. Beattie, Julia Bárdos, Roger J. Griffin, Ian R. Hardcastle, M. Raymond V. Finlay and Céline Cano. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Cancer Research, ACS Medicinal Chemistry Letters and Journal of Molecular Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marc R. ArnoneBreakdown of academic impact, for papers by Laura L. RokoszBreakdown of academic impact, for papers by Manfred SchudokBreakdown of academic impact, for papers by Karen L. MilkiewiczBreakdown of academic impact, for papers by Zhonghui LuBreakdown of academic impact, for papers by Mary Pat BeaversBreakdown of academic impact, for papers by Guoshun LuoBreakdown of academic impact, for papers by Angela SeatonBreakdown of academic impact, for papers by Rachel E. DavisBreakdown of academic impact, for papers by Asaad Nematalla